Wockhardt is an overall drug and biotechnology organization that produces expendable dose structures, injectable medications, biopharmaceutical drugs, oral medications, topically regulated medications(ointments or creams). Indian pharmaceutical and healthcare company Wockhardt Pharma Limited was established in 1967. Since that time we have been in the bleeding edge of the business’ advancement; a way that has been portrayed by improvement and foundation of itself as a global forerunner in the area.
Wockhardt Share Price Target 2024-2030
Over five decades ago, WOCKPHARMA was founded. In point of fact, this global reach accounts for approximately 67 percent of annual revenue. Wockhardt Pharma Restricted is an Indian medical care and drug endeavor, established in 1967. The multinational corporation operates in 30 nations and six continents around the world. On every continent and in thirty countries, multinational corporations operate.
Wockhardt Share Price Target Today Update
- As of right now, at 4:56 p.m. on Wednesday, the Wockhardt Pharma share price has dropped by 3.94 percent. When the National Stock Exchange opened for the day, the stock started at Rs 578 per share. Anyway NSE: WOCKPHARMA proceeded with its slump direction since the 1 Mrach high of Rs 620 for every offer.
- According to reports, on February 26, 2024, the healthcare and pharmaceutical company Wockhardt would raise Rs 400 crores on a priority basis and offer the QIP at an average price over the previous ten days.
- Wockhardt Pharma reported several years back about its coordinated effort with the UK based Serum Life Sciences. The goal of this partnership was to produce 150 million different vaccines in North Wales.
What is Wockhardt?
Wockhardt Pharma Share Price is an Indian-based medical services and drug organization that was laid out in 1967. It operates in 30 nations and six continents worldwide. The financial results for the company’s December quarter suggest that the stock will probably rise in the coming months. Nevertheless, it is essential to note that the company’s financial results for 2023 are unfavorable. The factors that influence Wockhardt Pharma’s NSE share price and the company’s share price target for 2025 and beyond will be discussed in this article.
Read More:-
Tata Investment Share Price Target
Mazagon Dock Share Price Target
Wockhardt Business Profile
The company is present in both the retail and hospital channels and is one of the three major Indian generic companies in the UK. It is also the sixth largest supplier of generics in Ireland. With a market share of 21.7 percent, its Wepox trademark is the bioequivalent of erythropoetin, while its Methylcobalamin trademark is the most popular.
Global Presence
The company operates fully in France, the United States, India, and the United Kingdom. It sells its other products in Russia, Brazil, Mexico, Vietnam, the Philippines, Nigeria, Kenya, Ghana, Tanzania, Nepal, Uganda, Mauritius, Myanmar, Sri Lanka, Lebanon, and Kuwait, among other emerging markets.
Vaccine Manufacturing
The UK Government and The Company came to an agreement to fill and finish COVID-19 vaccines that were made at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. The agreement stipulates that the company will keep its production capacity in order to provide the UK Government with a variety of vaccines, including AZD122, which was co-invented by Oxford University and licensed by AstraZeneca.
Manufacturing Capabilities
By establishing an inter-calibrated network of instruments, the company has established a multi-technology capacity that encompasses the production of all dose forms, from sterile injections to lyophilized products. The Food and Drug Administration of the United States, the European Medicine Agency, and the British Medicine and Health Product Regulatory Agency are the three organizations that oversee the 14 dynamically operating factories that are located in various nations around the world, specifically in India, Britain, and the United States. Each of these factories is supervised by highly skilled craftsmen on a daily basis.
Strategic Partnerships
Wockhardt and Wockhardt Bio AG, a subsidiary of the company and Jiangxi Jemincare Group Company Limited in China, collaborate on the production of an innovative antibiotic known as Nafithromycin, which Wockhardt owns a patent for. In response, CP Pharmaceuticals Limited, a subsidiary of the Company, and Serum Life Sciences UK have begun a global vaccine program with 150 million doses per year.
WOCKPHARMA Hospitals
In various regions of Gujarat and Maharashtra state, Wockhardt Hospitals owns six super-specialty hospitals. By providing high-quality healthcare and conducting cutting-edge research in the regenerative medicine field, including Stem Cells and Growth Factor Concentrate (GFC) Therapy for Hair Regrowth, Aesthetics, Orthopaedics, and Chronic Wound Healing, the hospital set the standard for clinical excellence.
Wockhardt Share Fundamentals & Quarterly Results
| Terms | Value |
| Market Cap | ₹ 8,238 Cr. |
| Current Price | ₹ 537 |
| High / Low | ₹ 630 / 167 |
| Stock P/E | |
| Book Value | ₹ 219 |
| Dividend Yield | 0.00 % |
| ROCE | -1.70 % |
| ROE | -13.4 % |
| Face Value | ₹ 5.00 |
| Debt to equity | 0.70 |
| Debt Capacity | -0.14 |
| Debt preceding year | ₹ 2,184 Cr. |
| Debt | ₹ 2,356 Cr. |
| Reserves | ₹ 3,282 Cr. |
| EPS | ₹ -30.2 |
| EPS last year | ₹ -30.2 |
| Pledged percentage | 52.9 % |
| FCF Prev Ann | ₹ 23.0 Cr. |
| EVEBITDA | 82.5 |
| Industry PE | 30.7 |
| PEG Ratio | |
| Piotroski score | 3.00 |
| Earnings yield | -1.01 % |
| Sales growth 5Years | -4.73 % |
Read More:-
Wockhardt Quarterly Results
| Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | |
| Sales + | 854 | 655 | 595 | 679 | 699 | 678 | 644 | 753 | 701 | 700 |
| Expenses + | 742 | 688 | 611 | 636 | 654 | 675 | 628 | 681 | 664 | 803 |
| Operating Profit | 112 | -33 | -16 | 43 | 45 | 3 | 16 | 72 | 37 | -103 |
| OPM % | 13% | -5% | -3% | 6% | 6% | 0% | 2% | 10% | 5% | -15% |
| Other Income + | 2 | -169 | 57 | -138 | -1 | -64 | 0 | 24 | 8 | 54 |
| Interest | 80 | 86 | 73 | 70 | 83 | 76 | 79 | 76 | 77 | 73 |
| Depreciation | 62 | 59 | 64 | 65 | 66 | 56 | 55 | 55 | 55 | 58 |
| Profit before tax | -28 | -347 | -96 | -230 | -105 | -193 | -118 | -35 | -87 | -180 |
| Tax % | 107% | 10% | 22% | 10% | 3% | -23% | -15% | -109% | 1% | 2% |
| Net Profit + | 2 | -311 | -75 | -207 | -102 | -237 | -136 | -73 | -86 | -177 |
| EPS in Rs | -0.49 | -17.91 | -4.65 | -13.12 | -6.66 | -14.44 | -9.30 | -5.34 | -5.76 | -11.02 |
WOCKPHARMA CAGR Report
| 10 Years | 5 Years | 3 Years | Last Year (TTM) | |
| Compounded Sales Growth | -5% | -5% | 1% | 6% |
| Compounded Profit Growth | -51% | |||
| Stock Price CAGR | 0% | 8% | -2% | 217% |
| Return on Equity | -1% | 0% | -8% | -13% |
Wockhardt Shareholding Pattern
| Shareholder Type | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
| Promoters + | 74.25% | 74.11% | 74.07% | 72.13% | 72.12% | 67.13% | 59.31% | 51.60% |
| FIIs + | 4.55% | 5.45% | 4.74% | 4.85% | 3.10% | 2.89% | 2.78% | 5.49% |
| DIIs + | 2.71% | 4.99% | 2.55% | 0.24% | 0.09% | 0.09% | 0.22% | 4.82% |
| Government + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% |
| Public + | 18.49% | 15.45% | 18.64% | 22.78% | 24.69% | 29.89% | 37.70% | 38.06% |
| No. of Shareholders | 1,24,403 | 99,736 | 1,14,338 | 1,17,324 | 1,25,488 | 1,72,460 | 1,82,493 | 1,46,138 |
Wockhardt Share Price Target 2024-2030 Forecast
| Year | Initial Target | Mid-Year Target | Year-End Target |
| 2024 | ₹529.44 | ₹660.8 | ₹739.61 |
| 2025 | ₹754 | ₹709 | ₹846 |
| 2026 | ₹863 | ₹811 | ₹968 |
| 2027 | ₹987 | ₹928 | ₹1108 |
| 2028 | ₹1130 | ₹1062 | ₹1267 |
| 2029 | ₹1292 | ₹1214 | ₹1450 |
| 2030 | ₹1479 | ₹1390 | ₹1660 |
WOCKPHARMA Share Price Target 2025
| Month | Target |
| January | ₹754 |
| February | ₹769 |
| March | ₹784 |
| April | ₹758 |
| May | ₹733 |
| June | ₹709 |
| July | ₹737 |
| August | ₹766 |
| September | ₹797 |
| October | ₹813 |
| November | ₹829 |
| December | ₹846 |
WOCKPHARMA Share Price Target 2026
| Month | Target |
| January | ₹863 |
| February | ₹880 |
| March | ₹898 |
| April | ₹868 |
| May | ₹839 |
| June | ₹811 |
| July | ₹843 |
| August | ₹877 |
| September | ₹912 |
| October | ₹930 |
| November | ₹949 |
| December | ₹968 |
Wockhardt Share Price Target 2027
| Month | Target |
| January | ₹987 |
| February | ₹1007 |
| March | ₹1027 |
| April | ₹993 |
| May | ₹960 |
| June | ₹928 |
| July | ₹965 |
| August | ₹1004 |
| September | ₹1044 |
| October | ₹1065 |
| November | ₹1086 |
| December | ₹1108 |
Wockhardt Share Price Target 2028
| Month | Target |
| January | ₹1130 |
| February | ₹1153 |
| March | ₹1176 |
| April | ₹1137 |
| May | ₹1099 |
| June | ₹1062 |
| July | ₹1104 |
| August | ₹1148 |
| September | ₹1194 |
| October | ₹1218 |
| November | ₹1242 |
| December | ₹1267 |
Read More:-
Wockhardt Share Price Target 2029
| Month | Target |
| January | ₹1292 |
| February | ₹1318 |
| March | ₹1344 |
| April | ₹1299 |
| May | ₹1256 |
| June | ₹1214 |
| July | ₹1263 |
| August | ₹1314 |
| September | ₹1367 |
| October | ₹1394 |
| November | ₹1422 |
| December | ₹1450 |
Wockhardt Share Price Target 2030
| Month | Target |
| January | ₹1479 |
| February | ₹1509 |
| March | ₹1539 |
| April | ₹1488 |
| May | ₹1438 |
| June | ₹1390 |
| July | ₹1446 |
| August | ₹1504 |
| September | ₹1564 |
| October | ₹1595 |
| November | ₹1627 |
| December | ₹1660 |
Points Before Investing in Wockhardt Stock
- In a CNBCTV18 report, a Market Expert had predicted a “Buy” call for the Wockhardt Share. The Wockhardt Pharma Share Price Target was evaluated by Mr. Shrikant Chouhan of Kotak Securities at Rs 500 in February 2024. The Kotak Securities analyst stated that the WOCKPHARMA NSE stop loss is Rs 450.
- In December 2023, Wockhardt Pharma’s net sales increased only marginally year over year. Drug Venture ”Wockhardt” net deals expanded by simply 2.13% to Rs 288 crores (Dec 2023) from Rs 282 crores (Dec 2022).
- In the fiscal year 2023, the healthcare and pharmaceutical company “Wockhardt Limited” based in India will see a decline in revenue of -17.93 percent (YoY) to Rs 26.51 billion.
- From FY2022 to FY2023, the Wockhardt Pharma company has struggled to maintain its negative financial results year over year. However, WOCKPHARMA: NSE was able to generate positive financial results for its investors during the December quarter of 2023.
Final Words
The company’s financial results for the December quarter and the share price of Wockhardt suggest that the stock will perform better in the coming months. However, Wockhardt Pharma Limited’s overall negative financial results in 2023 must be remembered. We will talk about the different elements that impact the Public Stock Trade share cost of Wockhardt Pharma and the Wockhardt Offer Value Focus through 2025.
Stay Updated with the Latest News and Trends
Discover the latest in tech, exams, Sarkari results, and more with our platform. We bring you fresh updates and expert insights to keep you informed and ahead. Join us today and stay on top of the most important developments!